Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

• Status: Recruiting
• Trial end date: 2023-06-16
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006 and MAS825 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006 and MAS825 have an adequate clinical profile for further clinical development.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Patients with moderate to severe HS based on the number of lesions, fistulae and anatomical areas involved

• Minimal body weight of 50 kg

• Able to communicate well with the investigator and understand and comply with the requirements of the study, and the ability and willingness to conduct study visits as per the study schedule

Exclusion Criteria:

• Use of other investigational drugs at the time of screening or before

• Women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception

• Pregnant or lactating women

Other protocol-defined inclusion/exclusion criteria may apply